Nov 07, 2023 / 09:30PM GMT
Yatin Suneja - Guggenheim Securities, LLC, Research Division - Senior MD & Equity Research Analyst
Good afternoon, everyone. My name is Yatin Suneja. I'm one of the biotech analysts here at Guggenheim. It is my pleasure to welcome all of you to our 5th Annual I&I Conference. This is day 2. And our next presenting company is Roivant.
From the company -- we have a couple of executives from the company here in our room, but I'm going to be chatting here with the Chief Executive Officer, Matthew Gline.
Matthew or Matt, why don't you maybe kick us off, make some opening comments, tell us what's going on at Roivant, what are some of the up-and-coming milestone that we should be focusing on? And then we'll go into a little bit more of a fireside session after that. Matt?
Matthew Gline - Roivant Sciences Ltd. - CEO & Director
Perfect. Yes. Thank you. Thanks for having us. Thanks, Guggenheim. It's a great privilege to participate in the conference. And obviously, thanks for all the great coverage as well. It's exciting to be here.
Roivant Sciences Ltd at Guggenheim Securities Inflammation & Immunology Conference Transcript
Nov 08, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers